SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
– Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg –
– Patients in 60 mg Dose Cohort Will be Dosed with 60 mg Once per Week or 30 mg Twice per Week –
Related news for (SLS)
- Afternoon Watchlist Builds as Busy Biotech, Blockbuster IPs & Big Institutional Bets Power Late-Day Surge
- MoBot’s Stock Market Highlights – 08/13/25 12:00 PM
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
- 24/7 Market News Snapshot 13 August, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)
- ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System